bioAffinity Technologies released a clinical case study on April 14, 2026, illustrating how its noninvasive CyPath® Lung test helped defer an unnecessary biopsy for a high-risk patient with a suspicious lung nodule.
Key takeaways
A new clinical case study was released illustrating CyPath® Lung's use in a patient with a 30-millimeter pulmonary nodule where imaging suggested cancer.
The test returned a negative 'Unlikely Malignancy' result, prompting follow-up imaging which showed the nodule had resolved, avoiding a biopsy.
CyPath® Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy for detecting lung cancer in small nodules in a prior clinical trial.
The case highlights the test's potential to assist in pulmonary nodule management by providing objective data to defer risky invasive procedures.
The company notes the case is illustrative of a single patient experience and does not establish generalized clinical utility.